Targeted therapies in Pulmonary arterial Hypertension (PAH)
4.2.3 Therapies targeting NO pathway: phosphodiesterase (PDE) type 5 inhibitors When compared with expression of PDE-5 in other tissues such as the penile corpus cavernosum and the myocardium, the expression and activity of PDE-5 is considerably higher in lung and in pulmonary vascular smooth muscle cells (Corbin, Beasley et al. 2005). ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- nursing ceus online no test required
- influence of sildenafil citrate on hypoglycemic activity
- الأسم هدى محمد جمال الدين دعبيس
- biointerface research in applied chemistry platinum open
- al al bayt university
- 1 0 background anzctr
- directions the questions in this section are based on the
- silodosin drug monograph veterans affairs
- 12 13 00 university of colorado denver
- targeted therapies in pulmonary arterial hypertension pah
Related searches
- symptoms of pulmonary arterial hypertension
- pulmonary arterial hypertension
- pulmonary arterial hypertension treatment
- pulmonary hypertension symptom in men
- diagnosis of pulmonary arterial hypertension
- systemic arterial hypertension icd 10
- pulmonary artery hypertension icd 10
- pulmonary hypertension in dogs
- pulmonary hypertension symptom in women
- pulmonary hypertension symptoms in dogs
- list of therapies in psychology
- uncontrolled arterial hypertension icd 10